• 3 September 2020
    Sequana Medical announces H1 2020 results and provides business update

    Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial results for the six-month period ending 30 June 2020 and its outlook for the remainder of the year and into 2021.

    Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “We have continued to make good progress towards key milestones in our two areas of strategic focus, liver disease / NASH in North America and heart failure in North America and Europe, despite the impact of COVID-19. Our POSEIDON pivotal study and RED DESERT repeated dose proof-of-concept study have both resumed and interim results are expected in H1 2021 and Q4 2020 respectively. Whilst not a core strategic focus, we are pleased to see the strong increase in European alfapump® revenue compared to the same period last year, underlining the patient need and demonstrating the positive impact of our targeted commercial strategy.

    “Since the start of this year, we have successfully secured additional funding that extends our cash runway into H2 2021. This enables us to reach key value inflection points and execute on our strategy of bringing the alfapump to more patients in two significant areas of medical need.”


    Download the full press release